PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsVinblastine
Vinblastine
Vinblastine (vinblastine) is a small molecule pharmaceutical. Vinblastine was first approved as Velban on 1982-01-01. It is used to treat breast neoplasms, choriocarcinoma, head and neck neoplasms, histiocytosis, and hodgkin disease amongst others in the USA. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
respiratory tract diseasesD012140
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Vinblastine (discontinued: Velban, Vinblastine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vinblastine sulfate
Tradename
Company
Number
Date
Products
VELBANEli LillyN-012665 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
vinblastine sulfateANDA2024-10-15
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CA: Vinca alkaloids and analogues, antineoplastic
— L01CA01: Vinblastine
HCPCS
Code
Description
J9360
Injection, vinblastine sulfate, 1 mg
Clinical
Clinical Trials
221 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.9958281999
Hodgkin diseaseD006689—C81657221586
Non-small-cell lung carcinomaD002289——1161110
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749—C671217—229
Transitional cell carcinomaD002295——2135—119
CarcinomaD002277—C80.01113—115
GliomaD005910EFO_0000520—472——12
MelanomaD008545——473——11
Lung neoplasmsD008175HP_0100526C34.90336——11
NeoplasmsD009369—C80423——8
Kidney neoplasmsD007680EFO_0003865C64242——7
RecurrenceD012008——131——5
Urethral neoplasmsD014523EFO_0003846——24——5
Show 22 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive hydatidiform moleD002820—D39.214———5
Breast neoplasmsD001943EFO_0003869C5024———5
Urologic neoplasmsD014571—C64-C68—4———4
Renal cell carcinomaD002292EFO_0000376——3———3
Central nervous system neoplasmsD016543——21———3
Nervous system neoplasmsD009423——21———3
Hiv infectionsD015658EFO_0000764B2013———3
Aggressive fibromatosisD018222—D48.11—2——13
Ewing sarcomaD012512EFO_0000173——2———2
Precursor cell lymphoblastic leukemia-lymphomaD054198———2———2
Show 32 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neoplasm metastasisD009362EFO_0009708—2————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AtaxiaD001259—R27.0————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
TelangiectasisD013684——————11
Cerebellar ataxiaD002524HP_0001251—————11
InfertilityD007246HP_0000789—————11
ConstipationD003248HP_0002019K59.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVinblastine
INNvinblastine
Description
Vincaleukoblastine is a vinca alkaloid, an indole alkaloid fundamental parent, a methyl ester, an acetate ester, a tertiary alcohol, a tertiary amino compound, an organic heterotetracyclic compound and an organic heteropentacyclic compound. It has a role as a microtubule-destabilising agent, an antineoplastic agent, a plant metabolite and an immunosuppressive agent.
Classification
Small molecule
Drug classantihistaminics (histamine-H1 receptor antagonists); vinca alkaloids
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Identifiers
PDB—
CAS-ID865-21-4
RxCUI—
ChEMBL IDCHEMBL159
ChEBI ID—
PubChem CID241903
DrugBankDB00570
UNII ID5V9KLZ54CY (ChemIDplus, GSRS)
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 24,857 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,023 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use